Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2

View ORCID ProfileRussell M. Petrak, View ORCID ProfileNicholas W. Van Hise, View ORCID ProfileNathan C. Skorodin, View ORCID ProfileRobert M. Fliegelman, View ORCID ProfileVishnu Chundi, View ORCID ProfileVishal Didwania, View ORCID ProfileAlice Han, View ORCID ProfileBrian P. Harting, View ORCID ProfileDavid W. Hines
doi: https://doi.org/10.1101/2020.10.27.20211433
Russell M. Petrak
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Russell M. Petrak
  • For correspondence: rpetrak@midcusa.com
Nicholas W. Van Hise
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas W. Van Hise
Nathan C. Skorodin
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nathan C. Skorodin
  • For correspondence: nskorodin@midcusa.com
Robert M. Fliegelman
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert M. Fliegelman
Vishnu Chundi
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vishnu Chundi
Vishal Didwania
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vishal Didwania
Alice Han
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alice Han
Brian P. Harting
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian P. Harting
David W. Hines
Metro Infectious Disease Consultants: Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David W. Hines
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background SARS-CoV-2 is a novel coronavirus that has rapidly expanded to become a pandemic, resulting in millions of deaths worldwide. The cytokine storm is caused by the release of inflammatory agents and results in a physiologic disruption. Tocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with SARS-CoV-2.

Methods This was a multi-center study of patients infected with SARS-CoV-2, admitted between 3/13/20 and 4/16/20, requiring mechanical ventilation. Parameters that were evaluated included age, sex, race, usage of steroids, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within one (1) day of intubation. Late dosing was defined as a dose administered greater than one (1) day after intubation. A control group that was treated only with standard of care, and without tocilizumab, was utilized for comparison (untreated).

Findings We studied 118 patients who required mechanical ventilation. Eighty-one (81) received tocilizumab, compared to 37 who were untreated. Early tocilizumab therapy was associated with a statistically significant decrease in mortality as compared to patients who were untreated (p=0.003). Dosing tocilizumab late was associated with an increased mortality compared to the untreated group (p=0.006).

Interpretation Early tocilizumab administration was associated with decreased mortality in critically ill SARS-Co-V-2 patients, but a potential detriment was suggested by dosing later in a patient’s course.

Funding This work did not receive outside funding or sponsorship.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work did not receive outside funding or sponsorship.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Western IRB 1019 39th Ave., SW Suite 120 Puyallup, WA 98374

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of Interest Statement: All other authors declared no competing interests for this work.

Data Availability

A deidentified dataset and the statistical analysis will be made available to the editor in chief or delegate for a period of 30 days from the time of submission for validation of results.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 28, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2
Russell M. Petrak, Nicholas W. Van Hise, Nathan C. Skorodin, Robert M. Fliegelman, Vishnu Chundi, Vishal Didwania, Alice Han, Brian P. Harting, David W. Hines
medRxiv 2020.10.27.20211433; doi: https://doi.org/10.1101/2020.10.27.20211433
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2
Russell M. Petrak, Nicholas W. Van Hise, Nathan C. Skorodin, Robert M. Fliegelman, Vishnu Chundi, Vishal Didwania, Alice Han, Brian P. Harting, David W. Hines
medRxiv 2020.10.27.20211433; doi: https://doi.org/10.1101/2020.10.27.20211433

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (140)
  • Anesthesia (44)
  • Cardiovascular Medicine (404)
  • Dentistry and Oral Medicine (66)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (168)
  • Epidemiology (4771)
  • Forensic Medicine (2)
  • Gastroenterology (172)
  • Genetic and Genomic Medicine (666)
  • Geriatric Medicine (69)
  • Health Economics (187)
  • Health Informatics (614)
  • Health Policy (312)
  • Health Systems and Quality Improvement (198)
  • Hematology (83)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5240)
  • Intensive Care and Critical Care Medicine (322)
  • Medical Education (88)
  • Medical Ethics (23)
  • Nephrology (72)
  • Neurology (674)
  • Nursing (41)
  • Nutrition (109)
  • Obstetrics and Gynecology (123)
  • Occupational and Environmental Health (203)
  • Oncology (435)
  • Ophthalmology (137)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (34)
  • Palliative Medicine (15)
  • Pathology (127)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (128)
  • Primary Care Research (82)
  • Psychiatry and Clinical Psychology (757)
  • Public and Global Health (1784)
  • Radiology and Imaging (315)
  • Rehabilitation Medicine and Physical Therapy (135)
  • Respiratory Medicine (254)
  • Rheumatology (86)
  • Sexual and Reproductive Health (67)
  • Sports Medicine (59)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)